APH vs INBX · P/E 40, rev $16.38B vs rev $1.3M
Amphenol Corporation (APH) versus Inhibrx Biosciences, Inc. (INBX) — a side-by-side from cached financials, not a winner call.
Amphenol Corporation (APH) is a electronic components company listed on US.
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
Latest reported APH revenue for 2026-06-30 was $16.38B. Net income was $2.70B. APH currently screens at market cap $170.77B and trailing P/E 39.9.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
APH currently screens at market cap $170.77B and trailing P/E 39.9. INBX currently screens at market cap $1.28B.
Not investment advice. Open the APH and INBX stock pages for the full models.
Not investment advice.